Venture capitalists in this industry have a lot weighing on their mind these days: an increasingly erratic regulatory process, new FDA leadership, healthcare reform, growing economic uncertainty in Europe, and the U.S. economy is just now beginning to rebound after a difficult 2008 and 2009.
